Beth Carter, MD

Dr Beth Carter is currently Clinical Professor of Pediatrics at Children’s Hospital Los Angeles/Keck USC School of Medicine. She joined CHLA in June 2018 as Medical Director of Intestinal Rehabilitation and Pediatric Liver Transplantation. Prior to CHLA, she served for 18 years as a Pediatric Transplant Hepatologist at Texas Children’s Hospital (Houston) as well as the founding Director of the Pediatric Intestinal Rehabilitation Program at Texas Children’s since 2007. She is board certified in both Pediatric Gastroenterology, Hepatology, and Nutrition as well as Pediatric Transplant Hepatology (Liver Transplant). Dr Carter’s longstanding research interests include both basic research in the molecular etiology of intestinal failure-associated liver disease (“IFALD”) as well as clinical IRB-approved trials/studies in various intravenous lipid emulsions used in pediatric short bowel syndrome (SBS). Dr Carter has served as Primary Investigator or Co-Investigator in all of the Pediatric teduglutide/GATTEX® SBS clinical trials to date across 2 centers—previously Texas Children’s and, more recently, as part of her role at Children’s Hospital Los Angeles. She is currently serving as CHLA Primary Investigator on the NIH-sponsored clinical trial for Pediatric Acute Liver Failure "TReatment for ImmUne Mediated PathopHysiology (TRIUMPH). A Phase 2b, Double-Blind, Three Arm, Randomize, Placebo Controlled Trial with Restricted Response Adaptive Randomization Testing the Efficacy and Safety of High Dose Methylprednisolone or Equine Anti-Thymocyte Globulin as Treatment for Acute Liver Failure in Pediatrics."